Home/Pipeline/MOTYS™

MOTYS™

Osteoarthritis

Phase 3Active

Key Facts

Indication

Osteoarthritis

Phase

Phase 3

Status

Active

Company

Doron Therapeutics

About Doron Therapeutics

Doron Therapeutics is a private, pre-revenue biotech founded in 2020, advancing a late-stage biologic for osteoarthritis (OA). The company's core asset, MOTYS™, is a placental tissue-derived biologic positioned as Phase 3-ready, targeting the significant unmet medical need in OA with a proposed mechanism of action combining anti-inflammatory, tissue-protective, and regenerative capabilities. Operating from San Diego, the company is poised to enter pivotal clinical trials, aiming to offer a new therapeutic option for a large and growing patient population with limited disease-modifying treatments.

View full company profile

Therapeutic Areas

Osteoarthritis Musculoskeletal

Other Osteoarthritis Drugs

Drug	Company	Phase	Status
MSC‑OA	Advancells	Phase 1	Active
Osteoarthritis program	Risen Pharma Tech	Clinical (China & US)	Active
ViscoCell™ for Osteoarthritis	Likarda	Pre-clinical	Active
Osteoarthritis Biologic Therapy	Ageless Biotech	Phase 2b	Active
PKM-011	PK MED	Pre-clinical	Active
CYT-108	Cytonics	Phase 2	Active
Topical PSGAG	ADORA Life Science	Pre-clinical	Active
FGF18 Gene Therapy	Remedium Bio	Pre-clinical	Active
Osteoarthritis Treatment Program	Biovico	Pre-clinical	Active
aGF	Scarcell Therapeutics	Phase 1	Active
Cartilage Repair	Sayenza Biosciences	Clinical	Active
BRM521	BRIM Biotechnology	Preclinical	Active